Citation

Baltenberger EP, Schmitt G, Thomas CJ. Ment. Health Clin. 2014; 4(3): 114-117.

Copyright

(Copyright © 2014, College of Psychiatric and Neurologic Pharmacists)

DOI

10.9740/mhc.n194575

PMID

unavailable

Abstract

Depression is the most common psychological condition in patients with cancer. These patients often have worse outcomes, such as decreased adherence to treatment and increased suicide rates. Since depression is common and often under recognized in this patient population, guidelines recommend screening every patient with cancer for depression. Both psychotherapy and pharmacotherapy are shown to be effective to treat depression in patients with cancer. Psychotherapy, specifically cognitive behavioral therapy, is preferred in patients with more mild depressive symptoms, while pharmacotherapy is used for more severe depression. Dignity therapy and supportive-expressive therapy are also recommended for patients near the end of life. Pharmacotherapeutic options for treatment include antidepressants and psychostimulants. Guidelines recommend SSRIs, SNRIs, or mirtazapine as first line treatment, with TCAs often avoided due to side effects. Psychostimulants, such as modafinil and methylphenidate, can be used as well, and are especially effective for patients near the end of life. SSRIs may also be useful to prevent the development of depression in patients taking drugs known to cause depression, such as interferon alfa. Treatment of depression in patients with cancer should be based on patient specific symptoms and situation. This article will review both nonpharmacologic and pharmacologic treatment options in patients with cancer and comorbid depression. © 2014 Mental Health Clinician. All rights reserved.

Language: en

Keywords

treatment; psychotherapy; depression; Cancer; pharmacotherapy